Amcor gets US approval for Alcan takeover

By Rory Harrington

- Last updated on GMT

Related tags European union Alcan

The US Department of Justice (DOJ) has given partial approval for Amcor’s takeover of Alcan after announcing it would now limit its review to Alcan’s Medical Flexible operations.

The Australian packaging giant announced last week the DOJ had halted the Hart-Scott-Rodino pre-merger waiting period. The decision by the US Government body effectively gives it the green light to proceed with its buyout of Alcan Packaging.

However, the US antitrust authority confirmed that it would continue its scrutiny of Alcan’s medical flexible business which is expected to take up to three months. During this period, the division will remain part of Rio Tinto. The business units consist of four sites with sales of around US$115m. The DOJ will deliver its verdict after making a “detailed review of the market”,​ confirmed Amcor.

“The decision by the U.S. Department of Justice allows closing to occur on all of the operations except Alcan’s Medical Flexibles operations in the US,”​ said a company statement.


This is not the first time competition concerns have been raised by regulatory authorities in the wake of the proposed US$2.025bn deal that Amcor tabled in August 2009 and Rio Tinto formally accepted in December.

Last month the European Union also gave the go-ahead for the deal on condition Amcor off-loaded the “major part”​ of its pharmaceutical flexible packaging business in the region. The company has agreed divest its Tobepal plants in Spain - which have combined sales of approximately €110 million and are part of the Amcor Flexibles division.

Brussels said “competition concerns in the European market for flexible packaging used in the pharmaceutical sector”​ had surfaced as a result of its initial investigation into the takeover.

Amcor managing director and CEO, Ken MacKenzie hailed the US decision on December 29 saying: “Receiving this approval from the U.S. Department of Justice is another critical step toward closing the Alcan Packaging acquisition.”

Regulatory approvals have now been granted in Europe, United States, Australia, Canada, Russia, Turkey and Ukraine.

Related news

Show more

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us